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Abstract
Renal insufficiency is common in patients with relapsed multiple myeloma and can often limit choice of therapy.
Lenalidomide, a critical agent in the treatment of relapsed multiple myeloma, is renally cleared., This phase I/II trial
evaluated the efficacy and safety of lenalidomide with dexamethasone in patients with relapsed multiple myeloma
and renal insufficiency. Three groups were treated, with creatinine clearance 30–60 cc/hr (group A), CrCl < 30 not on
dialysis (group B), and patients on dialysis (group C) at escalating doses of lenalidomide. A total of 63 patients were
treated and no DLTs were observed in phase I. All three groups were able to escalate to full dose lenalidomide 25 mg
daily 21/28 days, although due to reduced accrual the phase II component was not entirely completed for groups B
and C. Adverse events were as expected, including anemia, diarrhea and fatigue. Ten patients experienced grade 3–4
pneumonia. Overall response rate was 54% across all groups. PFS was 7.5 months and OS was 19.7 months.
Lenalidomide can be given at full dose 25 mg daily 21/28 in patients with a CrCl > 30, and can be given daily to those
with CrCl < 30, even when on dialysis, at doses of at least 15 mg daily.
Introduction
Multiple myeloma is diagnosed in approximately 30,000
Americans annually1 and remains an incurable hemato-
logic malignancy characterized by frequent early response
followed by universal treatment relapse necessitating
multiple sequential therapeutic regimens2. The most
commonly used backbone regimen for relapsed myeloma
employs lenalidomide and dexamethasone, eiher alone or
in combination with other novel agents or conventional
chemotherapy3.
Myeloma is more common among African-Americans
than among white patients (incidence rate of 13 cases/
100,000 vs. 5.6 cases/100,000). African-Americans are, in
turn, at higher risk for chronic kidney disease4. Lenali-
domide, while highly effective, is known to be sub-
stantially excreted by the kidneys, and the risk of toxic
reactions to this drug may be greater in patients with
impaired renal function5. Dysuria, renal failure, hema-
turia, acute renal failure, azotemia, calculus ureteric, and
renal mass are listed as reported adverse events in the
package insert.
Chen et al.6 conducted a multi-center study with lena-
lidomide 25mg a day as a single oral dose in five groups of
subjects defined by renal function: (1) normal (CrCl >
80mL/min); (2) mild (CrCl: >50–<80mL/min); (3) mod-
erate (CrCl: >30–<50mL/min); (4) severe (CrCl < 30mL/
min, but not on dialysis); (5) end stage renal disease
(ESRD)(requiring dialysis). Thirty subjects over the age of
35 were included in the study. Subjects with normal, mild,
moderate, or severe renal insufficiency received a single
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25mg oral dose of lenalidomide. Subjects with ESRD
received two single 25mg doses, separated by 7–10 days:
one dose on a non-dialysis day and the other dose 3 h
before a 4-h hemodialysis. This study demonstrated that
patients with renal insufficiency could be treated safely
and effectively with reduced dosing. Based on modeling to
produce AUCs in patients with renal insufficiency that
were comparable to those produced by full dose in
patients with normal renal function, the following doses
were recommended:
Renal function (CrCL) multiple myeloma
● Mild (CrCl ≥ 50mL/min) 25mg qd (Full Dose)
● Moderate (30 ≤CrCl < 50mL/min) 10mg qd*
● Severe (CrCl < 30mL/min, not requiring dialysis)
15 mg q 48 h
● ESRD (CrCl < 30 mL/min, requiring dialysis) 15 mg
3 × a week following each dialysis
*The dose may be escalated to 15mg qd after two cycles
if patient is tolerating drug well but not responding to
treatment
Since data on the maximum tolerated dose of lenali-
domide in patients with impaired renal function is lacking
and this remains a clinically significant issue, we under-
took this phase I/II trial in previously treated patients with
multiple myeloma and varying degrees of renal impair-
ment. The goal of the phase I component was to clinically
assess the MTD (maximum tolerated dose) per risk group.
In the phase II component, efficacy was assessed. This
trial was designed after the Chen et al.6 experience.
Subjects and methods
Patient selection
Subjects with previously treated multiple myeloma were
eligible to participate. They must have had measurable
disease, determined by one of the following assessed
within 21 days prior to registration: serum monoclonal
(M) protein ≥ 1 g by protein electrophoresis; urine m
protein ≥ 200mg on 24 h electrophoresis; serum immu-
noglobulin free light chain ≥10mg/dL with abnormal
serum immunoglobulin kappa to lambda free light chain
ratio; or monoclonal bone marrow plasmacytosis ≥30%
(considered evaluable disease). If both serum and urine
m-components were present, then both were required to
be followed for response evaluation. Patients must have
had ECOG performance status of 0, 1, or 2, and must have
completed previous therapy at least 2 weeks prior to study
entry. Patients were required to have renal impairment at
baseline, defined as serum creatinine clearance ≤60mL/
min, measured within 21 days prior to registration. Other
organ and marrow function was required to be acceptable
(absolute neutrophil count ≥ 1000 cells/mm3, platelet
count ≥ 75,000 cells/mm3, total bilirubin ≤ 2mg/dL, AST
(SGOT) and ALT (SGPT) ≤ 3 times the institutional
upper limit of normal.) Pregnant women were not eligible,
nor were females of childbearing potential unwilling to
use two forms or contraception or men unwilling to wear
a latex condom during sexual contact. Patients who had
previously received lenalidomide were eligible if they had
experienced a clinical response of any duration or a
progression-free interval of at least 6 months from the
start of that therapy. HIV-positive patients on combina-
tion antiretroviral therapy were not eligible, nor were
patients with known hypersensitivity to thalidomide or
other immunomodulatory drugs, patients with a history of
Stevens-Johnson syndrome, patients requiring concurrent
radiation therapy (other than for palliation of a single
bone lesion or fracture), or patients with another active
malignancy.
Registration
All patients provided signed, written informed consent.
During both phase I and phase II, patients were enrolled
concurrently into groups based on the degree of renal
impairment. Registration was completed through a web-
based data capture system. During phase I, registration
was preceded by telephone contact to assure that a place
on the protocol was available.
Treatment administration
Treatment began within seven working days after
registration and consisted of lenalidomide at the assigned
dose as shown in Table 1, dexamethasone 40mg orally on
days 1, 8, 15, and 22 of a 28 day cycle, and anticoagulation.
Anticoagulation consisted of aspirin at either 81 mg/day
or 325 mg/day at the physician’s discretion. Heparin, low
molecular weight heparin, or Coumadin could be used if
the patient was intolerant to aspirin.
Dose escalation phase: definition of dose limiting toxicity
Dose limiting toxicity (DLT) was defined as any of the
following events determined by the investigator to be
possibly, probably, or definitely related to lenalidomide
within the first cycle of therapy irrespective of whether the
adverse events resolved:
● Grade 3 or higher neutropenia with fever ≥ 38.5 °C
● Grade 4 neutropenia ≥ 7 days
● Grade 4 or higher thrombocytopenia
● Other non-hematologic grade 4 or higher adverse
event not present prior to starting therapy or not due
to underlying cause
In order to be evaluable for consideration of DLT, a
subject must have received at least one dose of both
lenalidomide and dexamethasone. Subjects who withdrew
before the end of cycle 1 for reasons other than adverse
events were to be replaced.
A standard 3+ 3 design was employed. First, three
patients were accrued to each group at a dose level,
starting with dose level 1. If zero of three patients
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experienced a DLT, then enrollment continued at the
next higher dose level. If two patients experienced a DLT,
then the recommended dose level would have been
exceeded. If one patient experienced a DLT, then three
more patients were accrued to the group and dose level. If
no additional patients experience DLT, then enrollment
continued at the next higher dose level. If any patients
among the additional three (total of two out of six)
experienced DLT, then the recommended dose would
have been exceeded. The recommended phase II dose was
the highest dose at which fewer than two of six patients
experienced DLT.
Post-cycle 1 lenalidomide and dexamethasone dose
modifications were specified in the protocol, as were
minimum ANC and platelet levels prior to treatment on
day 1 of each cycle. If patients in groups B or C had
improvement in renal function, they could receive a one-
time escalation in lenalidomide dose level after two cycles
of treatment had been completed. The protocol specified
criteria for ancillary treatment with growth factors,
infection prophylaxis, GI prophylaxis, and anti-
coagulation therapy.
Adverse events were carefully and routinely monitored
using the National Cancer Institute Common Terminol-
ogy Criteria for Adverse Events (CTCAE), Version 4.0.
Events of grade 1 and 2 that were deemed possibly,
probably or definitely related to treatment and all grade
3–4 adverse events were to be reported via case report
forms. All deaths within 30 days of the patient’s last study
treatment were to be reported, regardless of attribution, as
well as deaths after 30 days that were at least possibly
related to treatment. Serious adverse events were required
to be reported within 24 h of discovery. Pregnancy of a
female subject or the female partner of a male subject was
considered a serious adverse event.
Patients remained on treatment until disease progres-
sion, withdrawal of consent, or adverse events that in the
opinion of the investigator precluded further
participation.
Study monitoring
The study was conducted under the oversight of each
participating institution’s local Review Board. During the
phase I component of the study, weekly teleconference
calls were held to share information about accumulating
adverse events and general study conduct. The phase II
component of the study was monitored and reviewed
semi-annually by the PrECOG Data Safety Monitoring
Board. The trial is registered in clinicaltrials.gov
(NCT00790842).
Efficacy evaluation
Myeloma response criteria defined by the International
Myeloma Working Group were used to determine
response.
Table 1 Renal function groups, dose levels, and cycles administered
Renal function groups and dose levels
Group A Group B Group C
CrCl 30–60mL/min CrCl < 30mL/min, not on dialysis CrCl < 30mL/min, on dialysis
Dose level Dose (mg) Days Dose (mg) Days Dose (mg) Days
1 10 1–21 15 Every other day, days 1–21 15 3 × /wk, days 1–21
2 15 1–21 25 Every other day, days 1–21 10 1–21
3 25 1–21 15 1–21 15 1–21
4 – – 25 1–21 25 1–21
Number of cycles administered
Dose level n Median (range) n Median (range) n Median (range)
1 6 16.5 (2–48) 3 5 (2–10) 3 3 (3–4)
2 3 4 (2–23) 3 3 (3–24) 3 7 (3–34)
3 6 11 (3–47) 3 5 (3–35) 3 5 (1–27)
4 – 8 3.5 (1–24) 5 3 (2–6)
Expansion group 14 6 (1–20) 2 7.5 (6–9) –
Total patients 29 19 14
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Statistical considerations
The study was designed to have three independent
single-arm phase I trials to determine the recommended
phase 2 dose, followed by enrollment of 15 patients to
each trial for assessment of efficacy. The phase 1 groups
each followed a standard 3+ 3 design as described above.
This design provided a low probability of escalating if the
true DLT rate was high (17% for true DLT rates of 50%)
and a high probability of escalating if the true DLT rate
was low (91% for a DLT rate of 10%).
For the phase 2 component, the primary endpoint was
the proportion of patients who have at least a partial
response to treatment. The analysis was to include the six
patients treated at the recommended phase 2 dose in each
dose group, along with the additional patients enrolled to
the efficacy group for that dose group. The denominator
in estimating rates included all eligible, treated patients.
All dose groups were to be combined for the efficacy
analysis, so a total of 63 eligible, treated patients were
planned for analysis. The study was designed to distin-
guish a favorable response rate of 55% from a rate of 40%
not considered favorable. The decision rule stated that the
regimen would be considered efficacious if 31 or more
patients had a partial response or better. This design
provided 85% power to distinguish a favorable response
rate of 55% from a rate of 40%, using a one-sided test with
9% type 1 error.
Due to slower than anticipated accrual to the efficacy
group, a revised exploratory statistical analysis plan was
derived prior to final analysis. This plan would declare the
treatment worthy of further study if 18 or more of the 34
patients responded to treatment. This design had 84%
power to distinguish a response rate of 60% from a null
rate of 40%, using a one-sided test with 10% type I error.
Overall survival was defined as the time from registra-
tion to death or last contact. Progression-free survival was
defined as time from registration to documented pro-
gression or to treatment discontinuation due to progres-
sion. Patients without progression were censored at the
date of last disease assessment. Patients without disease
assessment follow-up dates post treatment were censored
at the last treatment date.
Response was classified into nine categories, ranging
from stringent complete response to progression. In order
to be considered a response for the efficacy analysis, a
classification of partial response or better was required.
Patients without follow-up disease assessments were
considered unevaluable, and were included in the
denominator when calculating the response rates.
Descriptive statistics were used to characterize patients
at study entry. Exact binomial confidence intervals (90%)
were computed for the response rates. The method of
Kaplan and Meier was used to estimate progression-free
and overall survival. Medians and 90% confidence
intervals were estimated for PFS (progression free survi-
val) and OS (overall survival). Mehta’s exact test for
ordered categorical data (1984) was used to compare
highest degree toxicity rates among groups. Stata (version
14.2) was used for all analyses.
Results
A total of 63 patients were enrolled between January
2009 and November 2015 from 12 different institutions
(nine institutions during phase 1). During the phase 1
component, one patient was found to be ineligible after
enrollment but prior to treatment and was excluded from
the analysis. Thus, the analysis group includes 62 patients.
Table 1 and Fig. 1 show the distribution of patients among
renal function groups and dose levels, along with analysis
cohorts for safety and efficacy.
Table 2 shows patient characteristics at baseline, by
renal function group and overall. Half of the patients were
female and 84% were Caucasian. Median age was 71.5
(range, 48–89). Over half of the patients had received at
least 2 prior treatment regimens.
Table 1 provides a summary of the number of cycles
administered, by dose level and renal function group.
Seventeen patients remained on treatment for more than
12 cycles.
During the phase I component of the study, no DLTs
were observed. Thus, the highest dose level tested in each
renal function group was selected for further evaluation.
Table 3 shows highest degree adverse events experienced
by each patient, tabulated by renal function group and
dose level. Twenty-eight patients experienced grade 3 or 4
treatment-related events. One patient in group C (the
dialysis group) assigned to dose level 2 experienced a
lethal adverse event reported as lung infection, sepsis, and
multi-organ failure. Five unrelated lethal events were
reported: cirrhosis, intra-abdominal hemorrhage, sudden
death, and ESRD (n= 2).
Group A  Group B Group C 
CrCl 30 – 60 mL/min  CrCl < 30 mL/min CrCl < 30 mL/min 
  Not on Dialysis On Dialysis 
Dose 1:  6  Dose 1:  3 Dose 1:  3 
Dose 2:  3  Dose 2:  3 Dose 2:  3 
Dose 3*: 6  Dose 3:  3 Dose 3:  3 
  Dose 4*:  8 Dose 4*: 5 
Total Safety Group:  15  Total Safety Group:  17 Total Safety Group:  14
Enrolled to Expansion 
Group*: 14 
 Enrolled to Expansion 
Group*:  2 
Enrolled to Expansion 




Assessed for Adverse 
Events: 29 
 Assessed for Adverse 
Events:  19 
Assessed for Adverse 
Events:  14 
Fig. 1 Disposition of cases
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Most common treatment related adverse events were
anemia, decreased appetite, and muscle weakness/fatigue.
Additionally, 11 episodes of grade 3 and 1 grade 4
pneumonia were reported for ten patients across all
groups and dose levels; four were considered possibly
related to treatment. Other grade 4 events, each occurring
in a single patient, were atrioventricular block, decreased
blood calcium, myocardial infarction, pancytopenia, per-
ipheral arterial occlusive disease, and septic shock.
As previously described, six deaths on study were noted.
One death from unknown cause within 30 days of the end
of treatment was also reported.
Supplementary Table 1 shows these same adverse
events broken down by two factors of interest: whether or
not the patient was assigned to a dose of at least 15 mg
per day, and whether or not the patient was assigned to a
daily dosing group. The distribution of highest degree
adverse events did not differ when comparing patients
who were assigned doses of at least 15 mg/day and those
assigned smaller doses (Fisher’s exact p= 0.28).
The distribution of highest degree adverse events did
not differ when comparing patients who were assigned to
daily doses and those assigned less frequent doses (Fish-
er’s exact p= 0.44).
Table 4 shows best overall response among 35 patients
who received the recommended phase II dose for their
renal function group. Across all groups, there were 19
responses, giving a rate of 54.3% (90% exact bionomial
confidence interval, 39.2–68.8%). This met the criteria for
success specified a priori using the revised analysis plan.
Response by dose and frequency can be viewed in Sup-
plementary Table 2.
Table 2 Patient Characteristics
Group A (n= 29) Group B (n= 19) Group C (n= 14) Total (n= 62)
n % n % n % n %
Creatinine clearance Median 42.6 22.8 11.5 27.4
Range 30.0–68.4 2.3–29.7 4.1–32.4 2.3–68.4
IQR 37.0–51.2 15.7–25.4 9.7–17.2 15.7–42.1
Missing 2 1 3
Serum M-spike (g/dL) <1 5 17.2 12 63.2 7 50.0 24 38.7
>=1 24 82.8 7 36.8 7 50.0 38 61.3
Urine M-spike (mg/24 h) <200 15 51.7 8 42.1 11 84.6 34 55.7
>=200 14 48.3 11 57.9 2 15.4 27 44.3
Serum IgFLC (mg/dL) <10 5 17.2 2 10.5 0 0 7 11.3
>=10 24 82.8 17 89.5 14 100.0 55 88.7
Bone marrow plasma cells (%) <30 16 55.2 11 57.9 7 50.0 34 54.8
>=30 13 44.8 8 42.1 7 50.0 28 45.2
Beta-2 microglobulin (mg/L) <3.5 3 10.3 1 5.3 1 7.1 5 8.1
>=3.5–<5.5 7 24.1 5 21.1 1 7.1 13 19.4
>=5.5 19 65.5 13 68.4 11 78.6 43 69.4
Albumin (g/dL) <3.5 11 37.9 7 36.8 8 57.1 26 41.9
>=3.5 18 62.1 12 63.2 6 42.9 36 58.1
Type of dialysis None 28 96.6 17 89.5 0 0 45 72.6
Peritoneal 0 0 0 0 2 14.3 2 3.2
Hemo-dialysis 1 3.5 2 10.5 12 85.7 15 24.2
Number of prior therapies 1 15 51.7 10 52.6 5 35.7 30 48.4
2–3 8 27.6 8 42.1 6 42.9 22 35.5
4 or more 6 20.7 1 5.3 3 21.4 10 16.1
IQR Interquartile Range
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There was no difference in response rate associated with
dose (<15 vs. ≥15mg/day, one-sided exact p= 0.43) or fre-
quency (daily vs. less frequently, one-sided exact p= 0.62).
Figure 2 shows progression-free survival among patients
in the efficacy analysis group. Median PFS was 12.6 months
(90% confidence interval, 10.5 to 21.8 months). There were
43 PFS events overall, 23 of which were among patients in
the efficacy analysis group. Twelve of these were progres-
sion events, five in the efficacy analysis group.
Figure 3 shows overall survival among patients in the
efficacy analysis group. At the time of study closure, 37
deaths had occurred, 21 in the efficacy analysis group.
Median overall survival was 20.0 months (90% confidence
interval, 12.5–42.1 months).
Discussion
Renal dysfunction is common, ranging from 20–50% in
myeloma and becomes increasingly important and more
aggressive in relapsed disease7–9. Indeed, one of the many
factors that heavily influences therapy selection in
relapsed multiple myeloma is renal function, due to its
prognostic influence, its comorbidity to the patient and in
the metabolism of anti-myeloma agents. It is also
important to note that many other non myeloma factors
can contribute to renal insufficiency in patients with
myeloma; in a series of nearly 200 patients who under-
went renal biopsy with myeloma and renal failure, 15%
had causes of renal failure that were not myeloma related,
including arterionephrosclerosis, diabetic nephrosclerosis,
postinfectious glomerulonephritis, and smoking related
gloomerulopathy10. Other plasma cell disorders asso-
ciated with renal compromise must also be excluded,
including amyloidosis and immunoglobulin deposition
disease.
Table 4 Best overall response—efficacy group




20 10 5 35
Response rate n (%) 12 (60.0%) 6 (60.0%) 1 (20.0%) 19 (54.3%)
90% CI 39.4–78.3% 30.4–85.0% 1.0–65.7% 39.2–68.8%
Fig. 2 Progression-free survival
Fig. 3 Overall survival
Table 3 Highest degree treatment-related adverse events
per patient, by renal function group and dose level
Highest degree treatment-related
Group Dose level Pts None 1 2 3 4 5
A 1 6 3 2 1
2 3 1 1 1
3 6 1 1 4
Expansion 14 1 4 3 6
B 1 3 1 1 1
2 3 1 1 1
3 3 1 1 1
4 8 1 1 2 3 1
Expansion 2 1 1
C 1 3 3
2 3 1 1 1
3 3 2 1
4 5 2 3
TOTAL 62 14 11 8 23 5 1
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Although many combinations are used in relapsed
myeloma, one of the key agents employed is lenalidomide.
It can be paired with dexamethasone alone11,12, but more
recently has been used in triplet therapy with dex-
amethasone plus carfilzomib13, ixazomib14 dar-
atumumab15, and elotuzumab16. It has also been
combined with more conventional chemotherapy such as
cyclophosphamide17 and bendamustine18.
Due to its renal clearance, clinicians are not well versed
in dosing of lenalidomide in patients with renal insuffi-
ciency, and may indeed be under-dosing or even over-
dosing patients—hence the need of the current study to
more clearly delineate the appropriate dosing of
lenalidomide.
As expected, the response rate was approximately 50%
in this high risk group of patients with renal insufficiency
in a real world setting. The response rate in the original
phase 3 trial of lenalidomide and dexamethasone was
50–63% in all renal subgroups, although the rate of
thrombocytopenia and dose delays/interruptions were
higher in the severe renal insufficiency group19. This has
been replicated in smaller studies of patients, where
lenalidomide and dexamethasone were given to patients
with renal insufficiency, including patients on dialysis20–23
in each of these series, a small but significant number of
patients experienced renal recovery.
It is somewhat surprising that in contrast to the product
insert and earlier findings in small number of patients, we
demonstrated that higher doses of lenalidomide could be
used safely in patients with renal impairment. Indeed,
those with a creatinine clearance of 30cc or greater (group
A patients) could receive full dose therapy of 25 mg daily
21/28 days, just like patients with normal renal function.
This is of great clinical utility as most patients do fall into
this category of mild renal impairment and dose mod-
ifications are not necessary, simplifying the dosing sche-
dule for clinicians.
This study also demonstrates the ability to continuously
dose patients with lenalidomide with severe renal insuf-
ficiency (CrCl < 30 but not on dialysis—group B), with at
least 15 mg and possibly 25 mg although too few patients
were treated to be conclusive. Similarly, 15–25mg daily
can be given to patients on dialysis (group C), avoiding the
inconvenience of three times weekly dosing. Overall, this
simplifies the dosing to daily dosing in all patients inde-
pendent of renal function with the caveat that dose
reduction to 15 mg may be required in patients with
severe renal insufficiency. We conclude this as over 20
patients were treated in both groups B and C daily and
with doses of 15 mg or greater. This is consistent with the
International Myeloma Working Group (IMWG)
recommendations, which also add that monitoring for
toxicity, namely myelosuppression should be considered
more carefully in patients with renal insufficiency24.
The greatest limitation of this study was challenging
accrual; with triplet combinations becoming more widely
used in relapsed multiple myeloma it was more difficult to
accrue to a doublet lenalidomide dexamethasone regimen.
Nonetheless, the number of patients accrued is the largest
in this group of patients and supports the conclusions
drawn.
Future studies should be conducted to explore the ideal
dosing of patients in triplet or even quadruplet combi-
nations—although in most of those combinations there is
a dose reduction in lenalidomide already.
Key points
1. In patients with CrCl ≥ 30 full dose lenalidomide
25 mg daily 21/28 is feasible and effective
2. In patients with CrCl < 30 (on dialysis or not)
lenalidomide can be given on a daily dosing regimen
(not three times weekly)
3. In patients with CrCl < 30 (on dialysis or not) can be
given lenalidomide at a dose of at least 15 mg daily
21/28
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